11 June
2024
Avacta Group
plc
("Avacta"
or the "Group" or the "Company")
Appointment of Nominated
Adviser and Sole Broker
Avacta Group plc (AIM: AVCT), a life
sciences company developing innovative, targeted oncology drugs and
powerful diagnostics, today announces the appointment of Peel Hunt
LLP as its Nominated Adviser and sole broker with immediate
effect.
-Ends-
For
further information from Avacta Group plc, please
contact:
Avacta Group plc
Christina Coughlin, Chief Executive
Officer
Tony Gardiner, Chief Financial
Officer
Michael Vinegrad, Group
Communications Director
|
Tel: +44
(0) 1904 21 7070
www.avacta.com
|
Peel Hunt LLP (Nomad and Sole
Broker) James Steel / Chris
Golden / Patrick Birkholm
|
Tel: +44 (0) 207 418 8900
www.peelhunt.com
|
ICR Consilium (Media and
IR)
Mary-Jane Elliott / Jessica Hodgson
/ Sukaina Virji
|
avacta@consilium-comms.com
|
|
|
About Avacta Group plc - https://www.avacta.com
Avacta Group is a UK-based life
sciences company focused on improving healthcare outcomes through
targeted cancer treatments and diagnostics.
Avacta has two divisions: A clinical
stage oncology biotech division harnessing proprietary therapeutic
platforms to develop novel, highly targeted cancer drugs, and a
diagnostics division focused on supporting healthcare
professionals.
Avacta has two proprietary
platforms, pre|CISION™ and Affimer®.
The pre|CISION™ platform is a highly
specific substrate for fibroblast activation protein (FAP) which is
highly upregulated in most solid tumours compared with healthy
tissues. The pre|CISIONTM platform harnesses this tumour
specific protease to activate pre|CISIONTM peptide drug
conjugates and pre|CISIONTM antibody drug conjugates in
the tumour microenvironment, reducing systemic exposure and
toxicity, allowing dosing to be optimised to deliver the best
outcomes for patients.
The lead pre|CISION™ programme
AVA6000, a peptide drug conjugate form of doxorubicin, is in Phase
1 studies. It has shown a dramatic improvement in safety and
tolerability compared with standard doxorubicin and preliminary
signs of clinical activity.
Affimer® is a novel
biologic platform which has significant technical and commercial
advantages compared with antibodies and can be used both to develop
advanced immunotherapies and to improve the performance of
immunodiagnostics.
To register for news alerts by email
go to https://avacta.com/investors/investor-news-email-alerts/